An Investigation of the Representativity of Neuropsychiatrists and their Patients in a Drug Utilization Observation Study on Fluoxetine

Abstract

This study presents a methodological approach to an expost facto investigation of sample bias in drug utilization observation (DUO) studies using the example of a DUO with the nontricyclic antidepressant fluoxetine. A total of 479 psychiatrists and neurologists and 2,401 patients were investigated. The purpose of the study was to judge the representativeness of our DUO sample for two populations: first, for all psychiatrics and neurologists prescribing fluoxetine or all patients being treated with fluoxetine in Germany and, second, for all psychiatrists and neurologists prescribing antidepressants or all patients being treated with antidepressants in Germany. Criteria for the representativeness test were physician variables (gender, size of community where practicing, federal state, age, volume of prescriptions) and patient variables (gender, age, prescription-related diagnosis, concurrent illnesses, concomitant medications). The study shows that the DUO sample can rightfully claim representativeness in the majority of parameters for the psychiatrists and neurologists prescribing fluoxetine and for the patients being treated with fluoxetine. There are more noticeable discrepancies with regard to the psychiatrists and neurologists in general and to the patients being treated with antidepressants in general. The methodological problems of pharmacoepidemiological investigation of representativeness are discussed.

Impact of the WHO depression guideline on patient care by psychiatrists: A randomized controlled trial

“…Only physicians with patients on mirtazepine prescriptions were included, as the manufacturer wanted to improve drug treatment as part of the overall patient management. In similar studies, it has been shown that such sampling results in an overrepresentation of prescribers of the target drug [23], so that the resulting sample of physicians is prototypically representative for this group of physicians.…”

Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride

“…In earlier studies it was shown that, by this procedure, physicians are selected who have special expertise with the target drug (Schaaf et al, 1997). Although payment for documentation was low in comparison with medical reimbursement guidelines, this also could have influenced the decision to switch to amisulpride or how to evaluate the course of treatment, as it is also known even from controlled clinical trials.…”

Correlates of low‐dosage treatment with antidepressants by psychiatrists and general practitioners

“…They were therefore not representative of all physicians but for the group of those who were experienced with this drug. 21 Patient selection or the mode of treatment were fully left to the discretion of the physicians as this was a prerequisite for studying the routine treatment and especially routine dosages. Treatment of 692 patients was recorded, that is 71.6% females and 28.4% males.…”